Delayed Hypersensitivity Reaction to Lenalidomide: 2 Different Clinical Patterns in the Same Patient

Noguerado-Mellado B1,3, Rojas-Pérez-Esquerra PD1,3, Tornero Molina P1,3, Ballesteros M2,3, Zubeldia Ortuño JM1,3

1Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
2Haematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
3Gregorio Marañón Health Research Institute, Madrid, Spain

Key words: Delayed. Desensitization. Hypersensitivity. Lenalidomide. Skin tests.


Lenalidomide is an immunomodulatory and antiangiogenic agent approved for the treatment of oncological and inflammatory diseases, such as multiple myeloma, myelodysplastic syndrome (MDS), and mantle cell lymphoma. It is administered alone or with dexamethasone in relapsed and refractory multiple myeloma or as maintenance therapy following autologous stem cell transplantation [1].

Lenalidomide has been associated with cutaneous eruptions [2]. Lowering the dose to prevent cutaneous reactions is ineffective [3,4]. Skin reactions have been described in approximately 21% of patients and are the most frequent adverse event with this drug [5].

Truly allergic reactions are difficult to distinguish from toxic adverse effects in patients receiving lenalidomide. Immediate and delayed hypersensitivity reactions are rare, with only a few cases reported, most of which did not involve a complete allergological work-up [6]. Hypersensitivity reactions include urticaria, exanthema, drug reaction with eosinophilia and systemic symptoms syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis [2,3,7].

We report a case involving both skin toxicity and a true delayed hypersensitivity reaction to lenalidomide.

The patient was a 78-year-old man with a history of prostate cancer in 2012 in complete remission and current del (5q) MDS type RAEB 1. He started treatment with 10 mg of lenalidomide for 21 days every 28 days. Following the second cycle, 3 days after the dose, he developed erythematous maculopapular exanthema on the thorax, back, and limbs, with no mucosal or systemic involvement. Oral corticosteroids were administered, and the reaction resolved within 15 days. Lenalidomide was discontinued, and he was referred to our allergy department. After signing an informed consent document, the patient underwent patch tests with lenalidomide at 10% in dimethyl sulfoxide (DMSO), and readings at day 2 and day 4 were negative. We performed patch tests with lenalidomide in DMSO because it is a useful vehicle that...
spreads the drug well on skin. Petrolatum and water are the most frequently used vehicles, although DMSO may be more adequate for certain drugs. There is no standardized version of skin tests or patch tests with this drug. A single-blind oral challenge test performed with 25 mg of lenalidomide was well tolerated. The drug was prescribed again, and the patient received a further 3 cycles without reactions. During the fourth cycle (6 in total), 3 days later, a generalized erythematous maculopapular exanthema appeared without eosinophilia and was treated with oral antihistamines and corticosteroids. The exanthema resolved in 7 days. Patch testing was repeated. The results were positive with lenalidomide 10% in DMSO on day 2 (++) and day 4 (++). The result of a control test with DMSO was negative (Figure). Similarly, the results of patch testing with lenalidomide were negative in 5 controls.

Since lenalidomide was indispensable for treatment of MDS and the patient had experienced a true delayed hypersensitivity reaction with no eosinophilia or severe clinical signs, we decided to administer the drug in a slow desensitization protocol.

The starting dose was 1 mg administered daily for a week and followed by 2.5 mg daily for a week, then 5 mg daily for a week. On the sixth day of the third week, the patient developed an erythematous maculopapular exanthema on his back, arms, and thorax. No eosinophilia or hepatic or renal involvement was observed. The patient was treated with oral antihistamines and tapering doses of 30 mg of corticosteroids for 5 days until the reaction disappeared. Desensitization was restarted a week after symptoms disappeared, with a reduced dose of lenalidomide (2.5 mg) for another week. Another generalized exanthema appeared on the seventh day, 3 hours after the last dose. The patient was treated with 60 mg of prednisone for 15 days. Corticosteroids were administered in tapering doses for a further 15 days because the symptoms did not remit. There were no residual lesions, desquamation, eosinophilia, or hepatic or renal involvement. At that point, desensitization was discontinued, and another desensitization protocol was proposed, although the patient refused.

We present a case of 2 different clinical patterns in the same patient. It was difficult to distinguish whether these were a cutaneous adverse reaction or hypersensitivity reaction.

To our knowledge, this is the first case of hypersensitivity reaction to lenalidomide confirmed by positive patch test results. Unfortunately, desensitization with lenalidomide was not achieved, probably because the patient’s reaction was a true delayed hypersensitivity reaction. All successfully desensitized cases reported in the literature are presumably because of toxicity to the drug and not because of an allergic reaction. Reports of successful desensitization to lenalidomide with similar protocols reveal no positive skin test results or allergology work-up [1,4,6,8,9]. Lee et al [1] reported 5 cases of successful slow desensitization to lenalidomide, achieving therapeutic doses of 10 mg after 6 weeks. If 25 mg was needed, the protocol was extended for a further week. As no skin tests were carried out on these patients, it was not possible to confirm the diagnosis. Desensitization to other oral drugs can be achieved in a slow protocol, in contrast with rapid desensitization in the case of immediate hypersensitivity reactions [10]. Cañamares et al [6] reported 2 patients with delayed exanthema after taking lenalidomide and a negative skin test result; both tolerated rapid desensitization.

There are no reports of positive skin test results and successful desensitization to lenalidomide in this kind of delayed reaction [10]. Reported cases occurred mostly after the first cycle and with no positive skin test results, possibly suggesting skin toxicity and thus leading to an erroneous diagnosis of an allergic reaction [1,4,6,8,9]. In the case we report, consistent with skin toxicity, the first reaction occurred after 2 cycles, although the second one appeared after 4 cycles (6 in total), with a positive patch test result. Therefore, a type IV hypersensitivity reaction was confirmed.

It is important to perform a complete allergology work-up in all patients in order to determine the etiologic mechanism of these skin reactions.

In conclusion, skin toxicity due to high doses of lenalidomide is frequent, and true allergic reactions may occur. While our protocol was not successful, the successful desensitization in delayed hypersensitivity reactions reported to date could be because the patients who experienced skin toxicity were not truly allergic patients [10]. More studies are needed to further investigate our findings.

Funding

The authors declare that no funding was received for the present study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References


Anaphylaxis to Clavulanic Acid: A 7-Year Survey

Silveira AM1, Gaspar Â2, Benito-Garcia F2, Couto S2, Matias J3, Chambel M2, Morais-Almeida M2

1Pulmonology Department, Fernando Fonseca Hospital, Amadora, Portugal
2Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal
3Pediatric Department, Garcia de Orta Hospital, Almada, Portugal

doi: 10.18176/jiaci.0390

Key words: Anaphylaxis. Clavulanic acid. Amoxicillin. Drug allergy.

Palabras clave: Anafilaxia. Ácido clavulánico. Amoxicilina. Alergia a medicamentos.

Clavulanic acid (CLV) is a β-lactam antibiotic with weak antibacterial activity, although it is a potent inhibitor of β-lactamases. The combination amoxicillin-CLV (AX-CLV) is widely used in clinical practice, and while most allergic reactions are due to amoxicillin [1,2], some allergic reactions to CLV may be selective. CLV was initially considered to have low immunogenicity, but in 1995, Fernandez-Rivas et al [3] reported the first 2 cases of selective anaphylaxis to CLV. Since then, other case reports showing selective hypersensitivity to CLV have been published [1,2,4-8].

Skin prick tests (SPTs) and intradermal tests (IDTs) followed by drug provocation testing (DPT) are the main diagnostic methods used to confirm hypersensitivity after immediate allergic reactions to β-lactams [9]. The purified CLV extract for testing (DAP Clavulanic, Diater) has been commercially available since 2012.

Hypersensitivity reactions to CLV are usually restricted to the skin, although rare anaphylactic reactions, some of which may be life-threatening, can occur [1-5,7]. Therefore, anaphylaxis to CLV must be carefully studied and selective hypersensitivity to CLV evaluated, since when confirmed, it enables the use of amoxicillin and other penicillins [1,7,8]. Nevertheless, studies on anaphylaxis to CLV are scarce.

The aim of this study was to evaluate and describe the frequency and clinical characterization of case reports of anaphylaxis to CLV based on the drug allergy work-up in patients with anaphylaxis caused by AX-CLV.

The study population comprised patients aged ≥6 years who were referred to the Drug Allergy Center of CUF-Descobertas Hospital, Lisbon, Portugal with suspected anaphylaxis to AX-CLV over a 7-year period (January 2011 to June 2018). Clinical data with a detailed description of symptoms and circumstances of the reaction were collected in the clinical history. The diagnostic procedures followed the recommendations of the European Network of Drug Allergy/European Academy of Allergy and Clinical Immunology [9,10].

Manuscript received October 29, 2018; accepted for publication February 6, 2019.

Blanca Noguerado-Mellado
Doctor Esquerdo, 46
28007 Madrid, Spain
E-mail: blancanoguerado@gmail.com